生物活性

• 描述Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias^[3]. Its primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic testing is used as an endpoint^[4]. Intravenous flecainide cardioversion could be a safe and effective option for emergency physicians to restore sinus rhythm in selected patients with acute AF (Atrial fibrillation) ^[5]. Flecainide is a well-tolerated medication, even at 12 months, with very minor adverse effects^[6]. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease^[7].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00578617	Atrial Fibrillation ... more >> Arrhythmia Collapse <<	Not Applicable	Completed	-	United States, Alabama ... more >> Universtity of Alabama Hospital Birminham, Alabama, United States, 35233 United States, California Good Samaritan Hospital Los Angeles, California, United States, 90017 United States, Illinois Loyola University Maywood, Illinois, United States, 60626 United States, Iowa Mercy Medical Center Des Moines, Iowa, United States, 50314 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Massachusetts Brigham and Womens Hospital Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55902 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pennsylvania Health Philadelphia, Pennsylvania, United States, 19104 United States, Utah Intermountain Medical Center Murray, Utah, United States, 84157 Collapse <<
  NCT03737929	Atrial Fibrillation	Not Applicable	Not yet recruiting	January 2022	France ... more >> CHU Toulouse, Hôpital Rangueil Not yet recruiting Toulouse, France, 31059 Contact: Philippe Maury, MD    05 61 32 34 56 ext +33    maury.p@chu-toulouse.fr    Contact: Anne Rollin, MD       rollin.a@chu-toulouse.fr    Principal Investigator: Philippe Maury, MD          Sub-Investigator: Anne Rollin, MD          Sub-Investigator: Bertrand Marcheix, MD          Sub-Investigator: Etienne Grunenwald, MD Collapse <<
  NCT00578617	-	-	Completed	-	-

• 更多
• 参考文献

• [1] Park SB, Vucic S, et al. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine. 2015 Dec 1;2(12):1916-22.

  [2] Apostolakis S, Oeff M, et al. Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother. 2013 Feb;14(3):347-57.

  [3] Velasco SL, Sierra-Hidalgo F, Rodríguez RM, Guerreo AJ, Morales JR. Flecainide-induced myoclonus. Clin Neuropharmacol. 2014 Mar-Apr;37(2):65-6

  [4] Falk RH, Fogel RI. Flecainide. J Cardiovasc Electrophysiol. 1994 Nov;5(11):964-81

  [5] Markey GC, Salter N, Ryan J. Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. J Emerg Med. 2018 Mar;54(3):320-327

  [6] Muzzey M, Tellor KB, Ramaswamy K, Schwarze M, Armbruster AL. Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study. Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720926824

  [7] Crozier I. Flecainide in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1992 Aug 20;70(5):26A-32A

• 更多

• Collapse